INTRODUCTION
B eing third among the most frequent cancers in men worldwide, and fourth in both sexes combined [1] , colorectal cancer (CRC) still has a high prevalence in the Romanian population, where it also ranks third in both men and women in what concerns incidence as well as mortality [2] . Geographical distribution varies a great deal in this type of cancer, with the highest rate of occurrence and mortality in more developed regions of the world, such asAs other types of cancer, CRC appears mainly as an outcome of various mutations accumulated in oncogenes and tumor suppressor genes, leading to an imbalance in apoptosis and proliferation, and a stimulation of angiogenesis pathways [3] . Apart from these molecular mechanisms involved in CRC tumorigenesis, there are other factors that contribute to the lethality of this disease, such as unhealthy dietary habits, use of harmful environmental agents and the failure to have the disease diagnosed in its early stages [4] . Looking at the 5-year survival of CRC patients, studies show that around 90 percent of the patients that receive their diagnosis close to the onset of the disease reach the 5-year landmark, while, on the other hand, no more than 10 percent survive that interval when diagnosed in the metastatic stages [5] .
Recent advances in science and technology have the potential to o er early diagnostic possibilities to clinicians through minimally invasive methods, through the discovery and development of specific biomarkers that can give information regarding a more precise staging of the disease, progression, prognosis, and response to particular therapeutic agents. Personalized medicine is the goal of today's medical J Gastrointestin Liver Dis, December 2014 Vol. 23 No 4: 413-418 community, but it cannot be attained without extensive studies targeted on the precise characterization of the "tumor genome". So far, numerous genetic studies have focused on the mutational status of genes with known implication in the development of CRC, such as BRAF, APC or KRAS [4] . Colorectal carcinogenesis is characterized by the successive accumulation of genetic and epigenetic alterations, all contributing to the alteration at transcription levels of key genes involved in the essential cellular processes [6] . One example is ICAM-1, a gene that mediates adhesion and migration but is also related to multiple in ammatory pathologies, including cancer [7] . TIMP-1 was proved to have antitumor properties [8, 9] , while other studies present contradictory e ects, such as stimulating tumorigenesis [10, 11] . It was observed that TGFβ1 modulates the MMPs/TIMPs balance, which is correlated to invasion via ERK1/2 pathway and Sp1 transcription factor [12] . Another controversial molecule is CDH1 (E-Cadherin) which was associated with multiple genetic variations. In CRC, most of the studies are related to gene polymorphisms, but they are still contradictory [13] .
e clinical outcome of CRC patients who receive the same medication is recognized to di er signi cantly, and consequently there is an urgent necessity to detect novel biomarkers for selecting the optimal therapy and for the prediction of patients' outcome [14] . Nonetheless, more attention needs to be directed to other cancer genes that take an active part in malignant transformation, and the way they behave in the particular context of CRC. erefore, our study is focused on observing the expression levels of several such genes in the tumor tissue of CRC patients, comparatively to the matched normal tissue from the same patients. e genes that were evaluated, CDH1, SMAD3, TGFβ1, ICAM-1, TIMP-1 and MUC12 are active players in tumorigenesis, and dysregulations in their expression patterns are characteristic to the development of the malignant phenotype.
MATERIAL AND METHODS
e study group consisted of 39 hospitalized patients, with pathologically con rmed CRC. e subjects included were patients diagnosed between April 2008 and February 2010, at the University 1 st Surgery Clinic in Cluj-Napoca, Romania. Epidemiological and clinical data were collected from the patients' medical records, and information regarding the vital status were obtained from the death records in the National Population Register. All patients signed an informed consent, and their personal information was handled according to the Declaration of Helsinki and the current EU con dentiality regulations. e epidemiological and clinical variables were: age at diagnosis, gender, tumor stage, presence of lymph node invasion, presence of distant metastases, and the grade of histopathological di erentiation. We chose as the endpoint the overall survival (OS), representing the period (months) from diagnosis to death. Overall survival was assessed a er a follow-up of minimum 3 years (36 months).
Sample collection
Collection of tumor and peritumoral tissue was performed during surgery. Samples were stored in liquid nitrogen until gene expression was determined, in order to evaluate the relative gene expression in tumor tissue versus normal tissue.
RNA extraction, quality control and assessment of gene expression
For the extraction of total RNA necessary for qRT-PCR evaluation of gene expression, we used the TriReagent (Sigma-Aldrich) protocol, and the quantitative and qualitative quantification was performed using the Nanodrop-1000 spectrophotometer (ThermoScientific), and the Agilent Bioanalyzer 2100. cDNA synthesis was performed using the Transcriptor First Strand cDNA Synthesis Kit kit (Roche), according to the manufacturer's recommendations.
For the qRT-PCR, we used the LightCycler®TaqMan® Master kit and the LightCycler 480 instrument from Roche. Speci c primers were used for each gene of interest (CDH1: GGT CTG TCA TGG AAG GTG CT / GAT GGC GGC ATT GTA GGT; SMAD3: CAC CAC GCA GAA CGT CAA / GAT GGG ACA CCT GCA ACC; TGFβ1: GCA GCA CGT GGA GCT GTA / CAT CCG GTT GCT GAG GTA; ICAM-1: CCT TCC TCA CCG TGT ACT GG / AGC GTA GGG TAA GGT TCT TGC; TIMP-1: GGG CTT CAC CAA GAC CTA CA / TGC AGG GGA TGG ATA AAC AG; MUC12: AGA AAT TTC ACA GAA AAG ATG AAT GA / CCC TTC AAA ACG ACA TCC A), as well as for the housekeeping gene β-actin (AGG AAT GGA AGC TTG CGG TA / AAT TTT CAT GGT GGA TGG TGC), together with the recommended probes (UPLRoche). Alterations of gene expression levels for the studied genes were evaluated using the ΔΔCt method [15] .
Statistical analysis
We correlated the epidemiological and clinical variables with gene expression (overexpressed/ underexpressed) as previously described by Chiorean et al [16] . A cut-o value of 65 years was chosen for the age. e relationship between qualitative variables was described using contingency tables with absolute values and percentages, Fisher's exact test, relative risk (RR) and risk di erence (RD) indicators.
In order to analyze whether the over-or underexpression of genes would in uence the risk of lethal outcome, the logrank test, Kaplan Meier curves and Cox proportional hazard regression models were used. A two-tailed p-value <0.05 was considered statistically signi cant for all tests. Statistical analysis was performed using Epiinfo, version 3.5.1.
RESULTS
Between January 2008 and June 2010, a number of 39 patients were included in the study, of whom 66% were males. e average age of the patients was 66 years. e clinical and pathological characteristic of the subjects included in our study are presented in Table I . Most of them were diagnosed with tubular adenocarcinoma (71%): 82% of the patients had colon cancer, and the remainder had rectal cancer.
Gene expression evaluation
RNA expression levels of CDH1, SMAD3, TGFβ1, ICAM-1, TIMP-1 and MUC12 were measured by qRT-PCR in the 39 tumor samples and their corresponding non-cancer tissue (Fig. 1 ). Signi cantly increased levels were observed for ICAM-1 and TIMP-1 when comparing tumor samples to the non-tumor group. We also observed a small increase in the gene expression level for TGFβ1, but it was not statistically signi cant for the evaluated CRC group. e associations between expressions of the genes are shown in Table II . A strong correlation was observed between the TIMP-1 and SMAD3 genes (rho = 0.54, p-value = 0.01). According to the location of tumors, we did not nd a signi cant di erence between gene expressions (p>0.05) for the evaluated genes in colon carcinoma versus rectal carcinoma. 
Fig. 1. Gene expression levels for the patients included in the study

Association between gene expression and epidemiological and clinical variables
Associations between expressions of genes as qualitative variables are shown in Table III Over-or underexpression in any of the genes were not signi cant risk factors for a lethal outcome (p>0.05). According to the Kaplan-Meier curves (Fig. 2, Table III) , overexpression of ICAM-1 was associated with lower OS rates after 10 months. Overexpression of MUC12 was associated with higher OS rates, a er 2 months. Underexpression of SMAD3 was associated with higher OS rates, between 2 and 30 months, while underexpression of TIMP-1 was associated with higher OS rates, between 2 and 25 months. e results were not statistically signi cant (p>0.05).
DISCUSSION
e objective of this study was to determine the prognostic value of a panel of six genes (CDH1, SMAD3, TGFβ1, ICAM-1,  TIMP-1 and MUC12 ) in CRC and to analyze their implication in the etiology of this disease. e literature shows that TIMP-1 (tissue inhibitor of metalloproteinase-1) is a candidate with biomarker potential, since its levels in the peripheral blood of CRC patients have been correlated with outcome and survival. In a study on 90 patients with metastatic CRC, Sorensen and colleagues hypothesized that high levels of TIMP-1 in the peripheral blood of these patients is correlated with gene overexpression in tumor tissue and can predict resistance to chemotherapy, as well as give clues regarding time to progression and overall survival. eir results showed that increased expression of this gene presented statistical correlation with the analyzed clinical parameters, which makes TIMP-1 a possible biomarker of great value for metastatic CRC patients, since only about half of them presently bene t from standard chemotherapy protocols [17] . ese ndings were sustained by other studies, such as that of Gong et al who showed the supportive e ect of TIMP-1 on tumor progression via cancer associated broblasts, and its potential of being used as a new target for anticancer therapy [18, 19] . Moreover, in a study by Lakatos et al, TIMP-1 was proposed as a biomarker, in tandem with MMPs (matrix metalloproteinases). In this study, the serum expression values for MMP-9 and TIMP-1 were recommended as supplementary biomarkers in the management of in ammatory bowel diseases (IBD) [20] . Some studies, such as those performed by Medina and colleagues, directly connect the overexpression of TIMP-1 and the activation of the TGFβ1 pathway via modulation of SMAD2/3 molecules [21] . Other studies con rm TIMP-1 overregulation in CRC samples compared with normal tissue. Moreover, TIMP-1 overexpression is connected with TGFβ1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 mRNA pro les modulation [22] . Although there was no statistical correlation between the upregulation of TIMP-1 and TGFβ1 in our samples, we still found a powerful association between TIMP-1 and SMAD3 (p=0.01), which strongly supports the idea of personalized treatment.
Our pilot study de nes a statistically signi cantly altered pattern of SMAD3, but this should be further evaluated and correlated with other genes in order to emphasize a prognostic value. It should be taken into account that the SMAD3 expression pattern is a consequence of multiple molecular events occurring within the tumor. However, this pilot assessment has not enough power for conclusions concerning the clinical signi cance of SMAD3 expression. Additional investigations on a larger cohort of patients with colorectal malignancies is required to characterize the role of SMAD3 in CRC, and especially the mechanism by which SMAD3 and TIMP-1 expression correlates with clinical outcome and prognosis.
At the same time, it is clear that SMAD3 is an essential transcription factor implicated in the TGFβ1 signaling pathway [23] . It was previously emphasized that the resistance to therapy in the case of choriocarcinoma in vitro models is due to the anti-invasive properties of TGFβ, and this is partially due to the inhibition of SMAD3 expression [24] . e correlations between TIMP-1 and SMAD3 should be further explored, since they might have signi cant potential in CRC, despite the fact that the change in the expression of SMAD3 was not statistically signi cant in our study.
In the CRC patients included in the study group, TGFβ1 expression level in the tumor tissue was higher than in the adjacent normal tissue, although not statistically signi cant. Literature data present TGFβ1 as being related to tumor size and tumor location [25] . In our study, we observed an overexpression of this gene in the tumor samples, but this was not statistically signi cant. is could be due to the small number of patients studied. Other studies revealed that TGFβ1 downregulation was correlated with a poor prognosis for stage III CRC patients [26] , while another study presented a panel of ve genes (TGFβ1, BIRC5, MYB, NR3C1, and TERT) as being crucial components of the colorectal carcinogenesis process [27] .
Although CDH1 overexpression was not statistically signi cant in the CRC samples, it was correlated with the presence of lymph node metastases. is gene might have a signi cant prognostic potential, due to the fact that genetic and epigenetic alterations are characteristic to CRC carcinogenesis. It was observed that the frequency of CDH1 promoter methylation in CRC tissue was higher than in non-tumor tissue [28] . A recent study proved that down-regulation of CDH1 and epithelial-mesenchymal transition (EMT) are considered crucial events in the activation of the invasion and metastasis mechanisms of CRC [29] .
In a similar study focused on the evaluation of genes that regulate EMT, alteration of CDH1 and VDR was observed [30] . SNAI1, ZEB1, CDH1 and vitamin D receptor (VDR) genes regulate the EMT that initiates the invasion process of many tumor cells. We hypothesized that this process could also a ect the behavior of normal cells which are located adjacent to the tumor.
CONCLUSION
Our study showed that the expression of the genes evaluated by quantitative RT-PCR had a certain amount of variation between the tumor tissue collected from CRC patients, and the corresponding normal tissue, but, in order to extend our understanding of the molecular mechanisms by which these genes take part in the development and progression of the malignant phenotype, this study should be further extended to a larger cohort of patients followed for a longer period which should also include a group of patients with in ammatory bowel disease (IBD). In spite of the limitations given by the reduced number of the cases we found a signi cantly increased gene expression levels in the malignant tissue for ICAM-1 and TIMP-1. ese variations did not present statistically signi cant correlations with clinical features, except for TIMP-1 and SMAD3 (p-value 0.01), this having potential prognostic signi cance.
